Why did RLMD's EPS remain stagnant throughout 2024?

The EPS of RLMD remained stagnant throughout 2024 due to several factors: 1. **Consistent Performance**: RLMD's EPS of ($0.59) for Q2 and Q3 2024, despite being below the breakeven point, indicates a consistent performance over the period. 2. **Analyst Estimates and Adjustments**: While there were adjustments in analyst estimates, with Leerink Partners increasing Q3 2024 EPS estimates from ($0.61) to ($0.47), the overall trend shows a decrease in expected EPS values over the full year, with the latest estimate at ($2.25) for FY2024. This suggests that the company's performance may not have improved significantly to increase EPS. |code|Ticker|Name|Date|Total Revenue|Net Income|Diluted EPS|market_code| |---|---|---|---|---|---|---|---| |RLMD|RLMD.O|Relmada Therapeutics|2024 Q1||-2.1828126E7|-0.72|185| |RLMD|RLMD.O|Relmada Therapeutics|2024 Q2||-1.7768122E7|-0.59|185| |RLMD|RLMD.O|Relmada Therapeutics|2024 Q3||-2.172597E7|-0.72|185| |RLMD|RLMD.O|Relmada Therapeutics|2024 Q4||-1.8657136E7||185| 3. **Revenue and Net Income**: The company reported a total revenue of ($-79.98 million) for the year, with no specific revenue figures for individual quarters available. The negative net income of ($-79.98 million) further indicates that the company is incurring significant losses, which could be a result of high research and development costs or operational inefficiencies. 4. **Institutional Activity**: Institutional investments, such as Mirae Asset Global Investments Co. Ltd.'s stake increase, suggest some confidence in the company's potential. However, these investments may not be directly related to the EPS performance, as they reflect a broader view of the company's prospects. In conclusion, RLMD's EPS remained stagnant due to a combination of consistent performance, adjustments in analyst estimates, and negative revenue and net income figures. The company's financial performance appears challenging, with significant losses reported for the year, which could impact its ability to improve EPS in the near term.